B7-H3–Targeting Chimeric Antigen Receptors Epstein-Barr Virus–specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3–positive Solid Tumors

• Published in: Cancer research communications Vol. 4; no. 6; pp. 1410 - 1429
• Main Authors: Yeo, Siok Ping, Kua, Lindsay, Tan, Jin Wei, Lim, Joanna Kristyn, Wong, Fiona HS, Santos, May Delos, Poh, Chek Meng, Goh, Angeline XH, Koh, Xin Yu, Zhou, Xiaohua, Rajarethinam, Ravisankar, Chen, Qingfeng, Her, Zhisheng, Horak, Ivan D., Low, Lionel, Tan, Kar Wai
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 04.06.2024
• Subjects: Animals; B7 Antigens - immunology; B7 Antigens - metabolism; Biological Agents & Therapies; Cell Line, Tumor; Female; Herpesvirus 4, Human - immunology; Humans; Immunology; Immunotherapy; Immunotherapy, Adoptive - methods; Mice; Neoplasms - immunology; Neoplasms - therapy; Receptors, Chimeric Antigen - immunology; Receptors, Chimeric Antigen - metabolism; Single-Domain Antibodies - immunology; T-Lymphocytes - immunology; T-Lymphocytes - metabolism; Translational Research; Xenograft Model Antitumor Assays
• ISSN: 2767-9764; 2767-9764
• DOI: 10.1158/2767-9764.CRC-23-0538

Encouraged by the observations of significant B7-H3 protein overexpression in many human solid tumors compared to healthy tissues, we directed our focus towards targeting B7-H3 using chimeric antigen receptor (CAR) T cells. We utilized a nanobody as the B7-H3-targeting domain in our CAR construct to circumvent the stability issues associated with single-chain variable fragment-based domains. In efforts to expand patient access to CAR T-cell therapy, we engineered our nanobody-based CAR into human Epstein-Barr virus-specific T cells (EBVST), offering a readily available off-the-shelf treatment. B7H3.CAR-armored EBVSTs demonstrated potent in vitro and in vivo activities against multiple B7-H3-positive human tumor cell lines and patient-derived xenograft models. Murine T cells expressing a murine equivalent of our B7H3.CAR exhibited no life-threatening toxicities in immunocompetent mice bearing syngeneic tumors. Further in vitro evaluation revealed that while human T, B, and natural killer cells were unaffected by B7H3.CAR EBVSTs, monocytes were targeted because of upregulation of B7-H3. Such targeting of myeloid cells, which are key mediators of cytokine release syndrome (CRS), contributed to a low incidence of CRS in humanized mice after B7H3.CAR EBVST treatment. Notably, we showed that B7H3.CAR EBVSTs can target B7-H3-expressing myeloid-derived suppressor cells (MDSC), thereby mitigating MDSC-driven immune suppression. In summary, our data demonstrate that our nanobody-based B7H3.CAR EBVSTs are effective as an off-the-shelf therapy for B7-H3-positive solid tumors. These cells also offer an avenue to modulate the immunosuppressive tumor microenvironment, highlighting their promising clinical potential in targeting solid tumors. Clinical application of EBVSTs armored with B7-H3-targeting CARs offer an attractive solution to translate off-the-shelf CAR T cells as therapy for solid tumors.